Tellus Therapeutics

[On Demand]
Search General Info
Search Education
Search Partnering Companies

Tellus is a mission-driven company dedicated to developing safe and effective treatments for unmet needs in newborns. Founded in October 2018, Tellus is translating breakthrough science licensed from Duke University in which compounds identified in breast milk induce the regeneration of myelin-producing oligodendrocytes and repair white matter injury (WMI) in an animal model of perinatal brain injury. As a preclinical stage life sciences start-up company, Tellus is focused on planning, funding and executing development programs to demonstrate safety and efficacy of new therapeutic interventions in newborns. Tellus aims to leverage institutional support, non-dilutive funding, equity investment and patient advocacy to discover, develop and commercialize a pipeline of products that improve care delivery, outcomes and lives of patients and families.


 


Tellus Therapeutics is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Not Provided
Lead Product in Development:
Not Provided
Development Phase of Primary Product:
Not Provided
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Tellus Therapeutics